FACTS ABOUT MASLD 

Nomenclature & Definition

1. MASLD stands for Metabolic dysfunction–Associated Steatotic Liver Disease.

2. The term was formally adopted in June 2023 through a multi-society Delphi consensus to replace "NAFLD" (nonalcoholic fatty liver disease).

3. The change was driven partly by concerns that "nonalcoholic" and "fatty" were stigmatizing and imprecise.

4. "Steatotic liver disease" (SLD) is now the overarching umbrella term for all causes of fat accumulation in the liver.

5. MASLD requires hepatic steatosis (fat in ≥5% of liver cells) plus at least one of five cardiometabolic risk factors.

6. MASH (Metabolic dysfunction–Associated Steatohepatitis) replaced the older term "NASH" (nonalcoholic steatohepatitis).

7. MASH is the more inflammatory, progressive form of MASLD involving liver cell injury.

8. MetALD is a newer category describing people with MASLD who also consume moderate amounts of alcohol.

9. The five cardiometabolic criteria include elevated BMI/waist circumference, high blood glucose or diabetes, high blood pressure, elevated triglycerides, and low HDL cholesterol.

10. Under the old NAFLD definition, the disease was diagnosed by excluding other causes; MASLD is defined by the presence of metabolic risk factors.

Prevalence & Epidemiology

11. MASLD affects roughly 30% of adults worldwide.

12. It is the most common chronic liver disease globally.

13. Prevalence has been rising in parallel with obesity and type 2 diabetes rates.

14. Among people with type 2 diabetes, prevalence may reach 55–70%.

15. Among people with severe obesity, prevalence can exceed 75%.

16. MASLD is increasingly diagnosed in children and adolescents.

17. It is a leading and growing cause of liver transplantation.

18. MASH is projected to become the top indication for liver transplant in several countries.

19. Prevalence varies by region, with some of the highest rates in the Middle East, South Asia, and Latin America.

20. Men are generally affected more than women before menopause, after which women's risk rises.

Risk Factors

21. Obesity is the single strongest risk factor, especially abdominal (visceral) fat.

22. Type 2 diabetes and insulin resistance are central drivers.

23. Metabolic syndrome dramatically increases risk.

24. High triglycerides and low HDL cholesterol are contributing factors.

25. High blood pressure is an associated cardiometabolic risk factor.

26. A diet high in refined carbohydrates, added sugars, and saturated fat raises risk.

27. Fructose, particularly from sugar-sweetened beverages, is linked to fat accumulation.

28. Physical inactivity and a sedentary lifestyle contribute.

29. Certain genetic variants (such as PNPLA3, TM6SF2, and HSD17B13) influence susceptibility and progression.

30. The PNPLA3 gene variant is associated with higher risk in some populations, including many of Hispanic ancestry.

31. Obstructive sleep apnea is associated with MASLD.

32. Polycystic ovary syndrome (PCOS) is a recognized risk factor.

33. Hypothyroidism and hypopituitarism can increase risk.

34. Rapid weight loss (including some bariatric scenarios) can occasionally worsen liver inflammation short-term.

35. It can also occur in people who are lean ("lean MASLD"), particularly with underlying metabolic dysfunction.

How It Develops (Pathophysiology)

36. It begins with excess fat (mainly triglycerides) stored in liver cells, called steatosis.

37. Insulin resistance promotes fat delivery to and storage in the liver.

38. In some people, steatosis progresses to inflammation and cell injury (MASH).

39. Ongoing injury can trigger scarring (fibrosis).

40. The "multiple hits" model describes how genetics, diet, gut bacteria, and metabolic stress combine to drive progression.

41. The gut microbiome is increasingly recognized as playing a role.

42. Oxidative stress and mitochondrial dysfunction contribute to liver cell damage.

43. Not everyone with steatosis progresses; many remain stable for years.

Symptoms & Detection

44. MASLD is often called a "silent" disease because early stages usually cause no symptoms.

45. When symptoms occur, they may include fatigue and vague discomfort in the upper right abdomen.

46. It is frequently discovered incidentally on imaging or through abnormal liver blood tests.

47. Liver enzymes (ALT, AST) may be mildly elevated—but can also be normal despite significant disease.

48. Ultrasound is a common first-line imaging test for detecting fatty liver.

49. Transient elastography (FibroScan) measures liver stiffness to estimate fibrosis and fat.

50. MRI-PDFF (proton density fat fraction) precisely quantifies liver fat and is often used in research.

51. Magnetic resonance elastography (MRE) is a highly accurate way to assess fibrosis.

52. Blood-based scores like FIB-4 and the NAFLD/MASLD Fibrosis Score help estimate fibrosis risk.

53. The Enhanced Liver Fibrosis (ELF) test is a blood biomarker panel for fibrosis.

54. Liver biopsy remains the gold standard for diagnosing MASH and staging fibrosis, though it's invasive.

55. Fibrosis stage (F0–F4) is the strongest predictor of long-term liver outcomes.

Progression & Complications

56. Fibrosis is staged from F0 (none) to F4 (cirrhosis).

57. Cirrhosis is advanced, largely irreversible scarring of the liver.

58. MASLD is a growing cause of cirrhosis worldwide.

59. It can lead to liver cancer, most commonly hepatocellular carcinoma (HCC).

60. Notably, MASLD-related liver cancer can sometimes develop even without cirrhosis.

61. Advanced disease can lead to liver failure requiring transplant.

62. Complications of cirrhosis include ascites, variceal bleeding, and hepatic encephalopathy.

63. Fibrosis progression is typically slow, often over years to decades.

64. Progression rates vary widely between individuals.

Associated Conditions & Whole-Body Impact

65. MASLD is strongly linked to cardiovascular disease.

66. Cardiovascular disease—not liver disease—is the leading cause of death in people with MASLD.

67. It is associated with an increased risk of type 2 diabetes developing over time.

68. It is linked to chronic kidney disease.

69. It is associated with certain extrahepatic (non-liver) cancers.

70. MASLD is considered by many experts to be the liver manifestation of metabolic syndrome.

71. It can coexist with other liver conditions, including viral hepatitis and alcohol-related liver disease.

72. It is associated with increased overall mortality risk compared to people without it.

Management: Lifestyle

73. Lifestyle modification is the cornerstone of management.

74. Losing about 5% of body weight can reduce liver fat.

75. Losing 7–10% of body weight can improve inflammation and even reverse some fibrosis.

76. The Mediterranean diet is one of the most evidence-supported eating patterns for MASLD.

77. Reducing added sugars, especially fructose-sweetened drinks, is commonly recommended.

78. Regular physical activity—both aerobic and resistance training—can reduce liver fat independently of weight loss.

79. Limiting or avoiding alcohol is generally advised, as alcohol can compound liver injury.

80. Coffee consumption has been associated in studies with lower risk of fibrosis progression (association, not a treatment).

81. Gradual, sustained weight loss is favored over rapid crash dieting.

82. Managing associated conditions—diabetes, cholesterol, blood pressure—is a key part of care.

Management: Medical & Emerging Treatments

83. In March 2024, the FDA approved resmetirom (Rezdiffra), the first drug specifically for MASH with fibrosis.

84. Resmetirom is a thyroid hormone receptor-beta agonist that targets liver fat metabolism.

85. GLP-1 receptor agonists (such as semaglutide), used for diabetes and weight loss, are being studied and show promise for MASH.

86. Vitamin E and pioglitazone have been used in select patients under specialist guidance.

87. Bariatric (metabolic) surgery can significantly improve MASLD in people with severe obesity.

88. Statins are generally considered safe in MASLD and important for cardiovascular risk.

89. Many additional drugs targeting metabolism, inflammation, and fibrosis are in clinical trials.

90. There is currently no single "cure"—management focuses on halting or reversing progression.

Special Populations & Broader Context

91. Pediatric MASLD is rising and can progress to significant liver disease in adulthood.

92. In children, the pattern of liver injury can differ from adults.

93. Lean individuals with MASLD may still face meaningful risk and warrant evaluation.

94. Some ethnic groups have higher genetic and metabolic susceptibility.

95. MASLD in people with diabetes tends to progress more aggressively.

96. Menopause is associated with increased MASLD risk in women.

97. The condition places a large and growing burden on healthcare systems worldwide.

98. Early detection and intervention offer the best chance to prevent advanced disease.

99. Fibrosis, especially at earlier stages, can improve with sustained metabolic health.

100. Awareness, screening in at-risk groups, and lifestyle change are central to reducing MASLD's long-term impact.